Try Alerts Free   |   Login
Health Care › Industrial Organic Chemicals

CDXS Price Correlated With Financials For Codexis

Free historical financial statements for Codexis Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 43 quarters since 2012. Compare with CDXS stock chart to see long term trends.

CDXS Stock Compared to Quarterly

CDXS Income Statement

Revenue, Net:34470000
Revenue Per Share:0.5248
Cost of Goods & Services Sold:9786000
Selling, General & Admin Expense:13499000
Research & Development Expense:21821000
Total Operating Expenses:45106000
Operating Income:-10636000
Income Taxes:8000
Net Income:-9992000
Earnings Per Share, Basic:-0.15
Shares Outstanding, Basic Avg:65687012

CDXS Cash Flow

Operating Activities Net Income:
Net Cash from Operations:19734000
Net Cash from Operations Per Share:0.3004
Net Cash from Financing Activities:133000
Property, Plant & Equipment Purchases:1310000
Net Cash from Investing Activities:-1309000
Net Change in Cash & Equivalents:18558000

CDXS Balance Sheet

Cash and Cash Equivalents:110737000
Accounts Receivable, Net:null
Total Current Assets:145997000
Property, Plant & Equipment, Net:23319000
Total Assets:235288000
Accounts Payable:2621000
Total Short-Term Liabilities:31908000
Total Liabilities:81157000

Major Holders (from 13F filings)

Investment Type
Value (x$1000)
increase or decrease
Baillie Gifford & Co
7,068,119 sh
-331,948 sh
Blackrock Inc.
5,481,593 sh
48,625 sh
Nantahala Capital Management, LLC
4,504,009 sh
4,454,009 sh
Ark Investment Management LLC
4,273,485 sh
-213,088 sh
Vanguard Group Inc
3,515,410 sh
29,276 sh
Telemark Asset Management, LLC
2,704,500 sh
200,000 sh
Ameriprise Financial Inc
1,960,888 sh
358,022 sh
1,826,357 sh
36,980 sh
Wellington Management Group Llp
1,554,069 sh
-83,180 sh
Gilder Gagnon Howe & Co LLC
1,459,913 sh
-511,431 sh
Nuveen Asset Management, LLC
1,406,777 sh
230,600 sh
Jacobs Levy Equity Management, Inc
1,327,668 sh
1,327,668 sh
State Street Corp
1,307,745 sh
18,118 sh
Goldman Sachs Group Inc
1,289,129 sh
-397,385 sh
Opaleye Management Inc.
1,155,000 sh
-133,450 sh
Sumitomo Mitsui Trust Holdings, Inc.
1,132,124 sh
19,180 sh
Nikko Asset Management Americas, Inc.
1,132,124 sh
19,180 sh
Geode Capital Management, LLC
1,124,573 sh
66,379 sh
William Blair Investment Management, LLC
1,090,412 sh
57,120 sh
Citadel Advisors LLC
787,769 sh
548,840 sh
Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation

The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") and include the accounts of Codexis, Inc. and its wholly-owned subsidiaries.

Certain prior year amounts have been reclassified in the Consolidated Statements of Cash Flows to conform to the 2021 presentation, however these reclassifications had no effect on the reported results of operations.

The consolidated financial statements include the accounts of Codexis, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of our consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. We regularly assess these estimates which primarily affect revenue recognition,

inventories, valuation of equity investments, goodwill arising out of business acquisitions, accrued liabilities, stock awards, and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the consolidated financial statements.

Segment Reporting

We report two business segments, Performance Enzymes and Novel Biotherapeutics, which are based on our operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker or decision making group (“CODM”), in deciding how to allocate resources, and in assessing performance. Our CODM is our Chief Executive Officer. Our business segments are primarily based on our organizational structure and our operating results as used by our CODM in assessing performance and allocating resources for the Company . We do not allocate or evaluate assets by segment.

The Novel Biotherapeutics segment focuses on new opportunities in the pharmaceutical industry to discover or improve novel biotherapeutic drug candidates that will target human diseases that are in need of improved therapeutic interventions. Similarly, we believe that we can deploy our platform technology to improve specific characteristics of a customer’s pre-existing biotherapeutic drug candidate, such as its activity, stability, or immunogenicity. The Performance Enzymes segment consists of biocatalyst products and services with focus on pharmaceutical, food, molecular diagnostics, and other industrial markets.

Foreign Currency Translation

The USD is the functional currency for our operations outside the United States. Accordingly, non-monetary assets and liabilities originally acquired or assumed in other currencies are recorded in USD at the exchange rates in effect at the date they were acquired or assumed. Monetary assets and liabilities denominated in other currencies are translated into United States dollars at the exchange rates in effect at the balance sheet date. Translation adjustments are recorded in other expense in the consolidated statements of operations. Gains and losses realized from non-USD transactions, including intercompany balances not considered as permanent investments, denominated in currencies other than an entity’s functional currency are included in other expense in the accompanying consolidated statements of operations.

Revenue Recognition

Our revenues are derived primarily from product revenue and collaborative research and development agreements. The majority of our contracts with customers typically contain multiple products and servic

Data imported from Codexis Inc SEC filings. Check original filings before making any investment decision.